Skip to content

Nicotinamide Mononucleotide Ameliorates Sleep Deprivation-Induced Gut Microbiota Dysbiosis and Restores Colonization Resistance against Intestinal Infections

Fang D, Xu T, Sun J, Shi J, Li F, Yin Y, et al. | Adv Sci (Weinh) | 2023 | Evidence: limited

Plain-language summary

Published 2023 in Adv Sci (Weinh), this work by Fang D and collaborators tackles a specific question within benefits-focused NMN/NAD+ research.

Key findings reported by the authors

  • Preclinical animal study in Adv Sci (Weinh) (2023) investigating NAD+/NMN pathway mechanisms
  • Findings inform translational rationale; not yet replicated in humans
  • Mechanistic data on tissue-specific NAD+ effects

What this means for Malaysian buyers

For readers in Malaysia weighing whether to start or continue NMN supplementation, this paper sits at the limited end of the evidence spectrum. Limited-tier evidence (mouse, in-vitro, or single small pilot) is hypothesis-generating only; do not extrapolate dosing or efficacy claims to humans without supporting replication. Findings here are most directly relevant to benefits decisions, with secondary relevance to science. Our editorial methodology weights human placebo-controlled trials above mouse mechanistic work above review articles.

← Back to research index